Muticenter trial on Apixavan or Edoxiavan for postoperative atrial fibrillation (Pilot study)

Muticenter trial on Apixavan or Edoxiavan for postoperative atrial fibrillation (Pilot study) - Muticenter trial on Apixavan or Edoxiavan for postoperative atrial fibrillation (Pilot study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037139

Enrollment

200

Registered

2019-06-22

Start date

2019-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

partial fibrillation after cardiac surgery

Interventions

Apixaban group(2.5mgX2/day or 5mgX2/day) Edoxaban group (30mgX1/day or 60mgX1/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: atrial fibrillation after cardiac surgery Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: Patients from whom informed consent was not obtained Hemodialysis Car<15 valve replacement surgery Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
Bleeding event Thromboembolic event	—

Secondary

Measure	Time frame
1) Hb, Ht, BUN, Cr, eGFR, AST, ALT 2) PT-INR, APTT 3) uric blood 4) Blood loss from drain, blood transfusion	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026